RecruitingNCT06909253

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis

Ravulizumab Treatment Outcomes in Patients With Generalized Myasthenia Gravis (gMG) Naive to Complement Inhibitors. Prospective, Multicenter, Non-interventional Study (MG-ARCADIA).

Sponsor

AstraZeneca

Enrollment

50 participants

Start Date

May 15, 2025

Study Type

OBSERVATIONAL

Conditions

Myasthenia Gravis, Generalized

Summary

The Polish multicentre observational (non-interventional) study aiming to collect data on the management and clinical outcomes of patients with gMG that received ravulizumab.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Ravulizumab for people with myasthenia gravis, generalized. The study is currently recruiting participants at 12 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGRavulizumab

Ravulizumab, concentrate for solution for infusion

Locations(12)

Research Site

Bydgoszcz, Poland

Research Site

Gdansk, Poland

Research Site

Katowice, Poland

Research Site

Krakow, Poland

Research Site

Lodz, Poland

Research Site

Lublin, Poland

Research Site

Poznan, Poland

Research Site

Poznan, Poland

Research Site

Szczecin, Poland

Research Site

Szczecin, Poland

Research Site

Warsaw, Poland

Research Site

Wroclaw, Poland

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06909253

Related Trials

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

NCT0750170224 locations

PANORAMA: Neuromuscular Organoids for Refractory AChR+ Myasthenia Gravis

NCT077172811 location

A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)

NCT076475101 location

Study of Aritinercept in Patients With Generalized Myasthenia Gravis

NCT075969013 locations

Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research

NCT048066201 location